Chronic Lymphocytic Leukemia Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Dr Graff talks about how the CLL treatment landscape has evolved in recent years.
View More
Dr Byrd shares results from a phase 3 trial on acalabrutinib versus ibrutinib for patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
View More
Paolo Ghia, MD, PhD, discusses the CAPTIVATE study of ibrutinib plus venetoclax in patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
View More
Paul Barr, MD, shares findings from the RESONATE-2 study of ibrutinib in patients with CLL/SLL. These data are being presented at the 2021 ASCO Annual Meeting.
View More
Dr Ahn discusses a 4-factor prognostic model to help predict the outcomes of ibrutinib therapy over chemoimmunotherapy in patients with CLL.
View More
Dr Rogers discusses her study on the combination of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.
View More
Dr Shah discusses his research on the use of a bi-specific anti-CD20/CD19 CAR-T therapy for patients with B-cell NHL or CLL.
View More
Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated…
View More
Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).
View More
Stay in the know.
OncNet Newsletter